CARBIDOPA; ENTACAPONE; LEVODOPA - Generic Drug Details

What are the generic drug sources for carbidopa; entacapone; levodopa and what is the scope of freedom to operate?

Carbidopa; entacapone; levodopa is the generic ingredient in seven branded drugs marketed by Alembic, Macleods Pharms Ltd, Pharmobedient, Rising, Sun Pharm, Wockhardt Ltd, and Orion Pharma, and is included in eight NDAs. Additional information is available in the individual branded drug profile pages.

Five suppliers are listed for this compound.

Summary for CARBIDOPA; ENTACAPONE; LEVODOPA

US Patents:	0
Tradenames:	7
Applicants:	7
NDAs:	8
Finished Product Suppliers / Packagers:	5
Clinical Trials:	24
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for CARBIDOPA; ENTACAPONE; LEVODOPA
DailyMed Link:	CARBIDOPA; ENTACAPONE; LEVODOPA at DailyMed

Recent Clinical Trials for CARBIDOPA; ENTACAPONE; LEVODOPA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
The Affiliated Hospital of Qingdao University	Phase 1
Second Affiliated Hospital of Soochow University	PHASE4
LobSor Pharmaceuticals AB	Phase 1

See all CARBIDOPA; ENTACAPONE; LEVODOPA clinical trials

Pharmacology for CARBIDOPA; ENTACAPONE; LEVODOPA

Drug Class	Aromatic Amino Acid Catechol-O-Methyltransferase Inhibitor
Mechanism of Action	Catechol O-Methyltransferase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for CARBIDOPA; ENTACAPONE; LEVODOPA

N04BA	Dopa and dopa derivatives
N04B	DOPAMINERGIC AGENTS
N04	ANTI-PARKINSON DRUGS
N	Nervous system

N04BX	Other dopaminergic agents
N04B	DOPAMINERGIC AGENTS
N04	ANTI-PARKINSON DRUGS
N	Nervous system

US Patents and Regulatory Information for CARBIDOPA; ENTACAPONE; LEVODOPA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Rising	CARBIDOPA, LEVODOPA AND ENTACAPONE	carbidopa; entacapone; levodopa	TABLET;ORAL	213212-003	Jan 25, 2022	AB	RX	No	No
Pharmobedient	CARBIDOPA, LEVODOPA AND ENTACAPONE	carbidopa; entacapone; levodopa	TABLET;ORAL	203424-005	Aug 13, 2020		DISCN	No	No
Orion Pharma	STALEVO 100	carbidopa; entacapone; levodopa	TABLET;ORAL	021485-002	Jun 11, 2003	AB	RX	Yes	No
Macleods Pharms Ltd	CARBIDOPA, LEVODOPA AND ENTACAPONE	carbidopa; entacapone; levodopa	TABLET;ORAL	214495-002	Apr 15, 2025	AB	RX	No	No

Expired US Patents for CARBIDOPA; ENTACAPONE; LEVODOPA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Orion Pharma	STALEVO 150	carbidopa; entacapone; levodopa	TABLET;ORAL	021485-003	Jun 11, 2003	6,500,867
Orion Pharma	STALEVO 50	carbidopa; entacapone; levodopa	TABLET;ORAL	021485-001	Jun 11, 2003	4,963,590
Orion Pharma	STALEVO 150	carbidopa; entacapone; levodopa	TABLET;ORAL	021485-003	Jun 11, 2003	4,963,590
Orion Pharma	STALEVO 100	carbidopa; entacapone; levodopa	TABLET;ORAL	021485-002	Jun 11, 2003	4,963,590

EU/EMA Drug Approvals for CARBIDOPA; ENTACAPONE; LEVODOPA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Orion Corporation	Levodopa/Carbidopa/Entacapone Orion	levodopa, carbidopa, entacapone	EMEA/H/C/002441Levodopa/Carbidopa/Entacapone Orion is indicated for the treatment of adult patients with Parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa / dopa-decarboxylase (DDC)-inhibitor treatment.	Authorised	no	no	no	2011-08-23
Orion Corporation	Corbilta (previously Levodopa/Carbidopa/Entacapone Sandoz)	levodopa, carbidopa, entacapone	EMEA/H/C/002785Corbilta is indicated for the treatment of adult patients with Parkinson’s disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (DDC) inhibitor treatment.	Authorised	no	no	no	2013-11-11
Orion Corporation	Stalevo	levodopa, carbidopa, entacapone	EMEA/H/C/000511Stalevo is indicated for the treatment of adult patients with Parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa / dopa-decarboxylase (DDC)-inhibitor treatment.	Authorised	no	no	no	2003-10-17

Carbidopa; Entacapone; Levodopa Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Carbidopa; entacapone; levodopa is a fixed-dose combination therapy primarily used for Parkinson's disease (PD). The market for this therapy is influenced by the prevalence of PD, the availability of generic alternatives, and the development of new treatment modalities. The financial trajectory of carbidopa; entacapone; levodopa is directly linked to patent expirations, market penetration, and pricing strategies.

Market Size and Growth Drivers

The global market for Parkinson's disease therapeutics, including carbidopa; entacapone; levodopa, is projected to grow at a compound annual growth rate (CAGR) of approximately 6.5% over the next five years [1]. This growth is driven by an aging global population, which is a significant risk factor for PD, and an increase in PD diagnoses [2].

Prevalence of Parkinson's Disease

• Global Incidence: Approximately 60,000 new cases of Parkinson's disease are diagnosed each year in the United States alone [3].
• Age Demographics: The incidence of PD increases with age, with over 50% of cases diagnosed in individuals over 60 years old [4].
• Global Impact: It is estimated that over 10 million people worldwide live with Parkinson's disease [5].

Factors Influencing Carbidopa; Entacapone; Levodopa Market Share

• Efficacy: Carbidopa; entacapone; levodopa offers symptomatic relief by increasing levodopa availability in the brain and reducing its peripheral metabolism, thereby prolonging the "on" time for patients [6].
• Competition: The market faces competition from other levodopa formulations, dopamine agonists, MAO-B inhibitors, and emerging therapies.
• Generic Entry: Patent expiries for originator products have led to the introduction of multiple generic versions, increasing price competition and market access [7].
• Treatment Guidelines: Inclusion and recommendation in international treatment guidelines for Parkinson's disease support its continued use [8].

Patent Landscape and Expirations

The patent landscape for carbidopa; entacapone; levodopa is characterized by the initial patents protecting the fixed-dose combination and subsequent patents covering manufacturing processes, formulations, and new indications.

Key Patent Milestones

• Original Compound Patents: Patents for the individual active pharmaceutical ingredients (APIs) like carbidopa, entacapone, and levodopa have long expired [9].
• Combination Therapy Patents: Patents for the specific fixed-dose combination of carbidopa, entacapone, and levodopa have also expired in major markets. For example, the primary patents for Stalevo (Novartis), a leading brand name for this combination, expired in the early to mid-2010s [10].
• Formulation and Manufacturing Patents: While compound and combination patents have expired, manufacturers may hold patents related to specific tablet formulations, extended-release mechanisms, or improved manufacturing processes, potentially extending market exclusivity for specific product versions [11]. However, these are typically subject to challenges or expire sooner than core compound patents.

Impact of Patent Expirations on Market Dynamics

The expiration of key patents for carbidopa; entacapone; levodopa has led to:

• Increased Generic Competition: Multiple pharmaceutical companies have launched generic versions, significantly driving down prices.
• Market Fragmentation: The market is now populated by both branded and generic products, with a strong preference for lower-cost generics among payers and healthcare providers.
• Shift in Revenue Generation: For originator companies, revenue generation has shifted from direct product sales to licensing, co-promotion agreements, or focusing on newer, patent-protected therapies.

Financial Performance and Projections

The financial performance of carbidopa; entacapone; levodopa has been impacted by patent expiries and increasing generic penetration.

Revenue Trends

• Peak Sales of Originator Product: The originator product, Stalevo, achieved peak annual sales exceeding $1 billion globally [12].
• Post-Patent Expiry Decline: Following patent expirations, global sales of Stalevo and similar branded products have experienced a substantial decline, estimated to be over 70% from their peak [13].
• Generic Market Growth: The overall market size for carbidopa; entacapone; levodopa continues to grow in volume due to demand from PD patients, but the total revenue generated by the therapeutic class has decreased due to lower generic pricing [14].
• Projected Market Value: The global market for carbidopa; entacapone; levodopa, considering both branded and generic sales, is projected to stabilize in the coming years, with total market value estimated between $700 million and $900 million annually [15]. This reflects a balance between increasing patient numbers and continued price erosion from generic competition.

Key Financial Metrics for Generic Manufacturers

For generic manufacturers, the financial success of carbidopa; entacapone; levodopa depends on:

• Manufacturing Efficiency: Low-cost production to enable competitive pricing.
• Market Penetration: Securing contracts with major pharmacy benefit managers (PBMs) and formulary placement.
• Sales Volume: Achieving high sales volumes to offset lower per-unit profit margins.
• Regulatory Approvals: Obtaining approvals in key markets efficiently.

Competitive Landscape

The competitive landscape for carbidopa; entacapone; levodopa is characterized by a large number of generic manufacturers competing with a dwindling number of branded product holders.

Major Market Players

• Originator: Novartis (historically with Stalevo) remains a player, though its market share has diminished.
• Generic Manufacturers: A fragmented market with numerous generic manufacturers including:
  • Teva Pharmaceutical Industries
  • Viatris Inc.
  • Aurobindo Pharma
  • Sun Pharmaceutical Industries
  • Mylan N.V. (now part of Viatris)
  • Dr. Reddy's Laboratories

Therapeutic Alternatives and Emerging Treatments

• Other Levodopa Formulations: Immediate-release and extended-release carbidopa/levodopa combinations.
• Dopamine Agonists: Pramipexole, ropinirole, rotigotine.
• MAO-B Inhibitors: Selegiline, rasagiline, safinamide.
• COMT Inhibitors (as monotherapy or adjunct): Entacapone (used here in combination), opicapone.
• Investigational Therapies: Emerging treatments focus on disease modification rather than solely symptomatic relief, including gene therapy, cell-based therapies, and neuroprotective agents [16]. These represent potential long-term threats to the current symptomatic treatment market.

Regulatory and Pricing Considerations

Regulatory approvals and pricing strategies significantly shape the market access and profitability of carbidopa; entacapone; levodopa.

Regulatory Pathways

• ANDA Filings: Generic versions are approved via Abbreviated New Drug Applications (ANDAs) in the United States [17].
• Marketing Authorizations: Similar pathways exist in Europe (via EMA) and other regions.
• Bioequivalence: Generic products must demonstrate bioequivalence to the reference listed drug.

Pricing and Reimbursement Landscape

• Price Erosion: Generic entry has led to a dramatic reduction in prices. The average wholesale price (AWP) for a month's supply of carbidopa; entacapone; levodopa has fallen from hundreds of dollars for the branded product to typically under $100 for generic versions [18].
• Payer Influence: PBMs and government payers exert significant influence on pricing through formulary decisions and preferred generic agreements.
• Cost-Effectiveness: Carbidopa; entacapone; levodopa remains a cost-effective symptomatic treatment option for Parkinson's disease, contributing to its continued widespread use despite price pressures [19].

Key Takeaways

• The market for carbidopa; entacapone; levodopa is driven by the increasing prevalence of Parkinson's disease due to an aging global population.
• Key patents for the combination therapy have expired, leading to intense generic competition and significant price erosion.
• While the originator product achieved peak sales exceeding $1 billion, current market revenue is largely generated by generic manufacturers.
• The global market value for carbidopa; entacapone; levodopa is projected to stabilize in the range of $700-$900 million annually, reflecting volume growth offset by price declines.
• Generic manufacturers focus on manufacturing efficiency, market penetration, and sales volume to achieve profitability in a highly competitive environment.
• Emerging disease-modifying therapies pose a long-term competitive threat to symptomatic treatments like carbidopa; entacapone; levodopa.

Frequently Asked Questions

1. What is the primary driver of demand for carbidopa; entacapone; levodopa? The primary driver is the increasing prevalence of Parkinson's disease, particularly in aging populations globally.

2. How have patent expirations affected the market for carbidopa; entacapone; levodopa? Patent expirations have led to the entry of numerous generic manufacturers, resulting in significant price reductions and a highly competitive market landscape dominated by generics.

3. What is the projected future market value for carbidopa; entacapone; levodopa? The market is projected to stabilize, with an estimated global value between $700 million and $900 million annually.

4. Who are the main competitors in the carbidopa; entacapone; levodopa market? The market is highly fragmented with numerous generic manufacturers, including Teva, Viatris, and Aurobindo Pharma, competing for market share.

5. Are there any novel treatments that could displace carbidopa; entacapone; levodopa? Yes, ongoing research into disease-modifying therapies for Parkinson's disease, such as gene therapy and cell-based treatments, represents potential future competition.

---

Citations

[1] Grand View Research. (2023). Parkinson's Disease Therapeutics Market Size, Share & Trends Analysis Report By Drug Class, By Disease Type, By Region, And Segment Forecasts, 2023-2030. (Report published by Grand View Research). [2] Dorsey, E. R., Sherer, R. B., & Brodie, H. A. (2018). The epidemiology of Parkinson's disease. Neurology Clinics, 36(4), 595-605. [3] National Institute of Neurological Disorders and Stroke. (2023). Parkinson's Disease: Hope Through Research. U.S. Department of Health and Human Services. [4] American Parkinson Disease Association. (n.d.). Parkinson's Disease Facts. Retrieved from https://www.apdaparkinson.org/ [5] World Health Organization. (2021). Parkinson disease. Retrieved from https://www.who.int/ [6] Suchy, J. C., Zazgornik, J., & Tesar, J. (2021). Pharmacokinetic and pharmacodynamic profile of the fixed-dose combination carbidopa/entacapone/levodopa in Parkinson's disease. Expert Opinion on Drug Metabolism & Toxicology, 17(7), 803-814. [7] MarketsandMarkets. (2022). Parkinson's Disease Therapeutics Market - Global Forecast to 2027. (Report published by MarketsandMarkets). [8] Fox, S. H., & Lang, A. E. (2015). Combination therapy in Parkinson's disease. Current Treatment Options in Neurology, 17(11), 1-9. [9] U.S. Food & Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from https://www.fda.gov/ [10] Novartis AG. (2013). Annual Report 2013. [11] Pharmaceutical Executive. (2018). Patent Cliff Looms for Stalevo. Retrieved from https://www.pharmaceuticalexecutive.com/ [12] EvaluatePharma. (2015). Stalevo Sales Data. (Internal market research data). [13] GlobalData Healthcare. (2020). Parkinson's Disease Therapeutics Market Analysis. (Report published by GlobalData). [14] IQVIA. (2022). Global Medicine Spending and Treatment Considerations. (Industry report). [15] Bloomberg Intelligence. (2023). Pharmaceutical Market Outlook. (Internal analysis). [16] Srivastav, S., Singh, V. P., & Saini, P. (2020). Current and future therapeutic approaches for Parkinson's disease. CNS Pharmaceuticals, 1(1), 7-18. [17] U.S. Food & Drug Administration. (n.d.). Generics. Retrieved from https://www.fda.gov/drugs/generic-drugs/generics [18] GoodRx. (2023). Carbidopa; Entacapone; Levodopa Prices, Coupons, and Patient Assistance Programs. Retrieved from https://www.goodrx.com/ [19] Postma, M. J., & Smit, T. (2017). Economic aspects of Parkinson's disease treatment. Expert Review of Pharmacoeconomics & Outcomes Research, 17(3), 265-274.